Telomir Pharmaceuticals demonstrates promising anti-cancer activity of Telomir-Zn in preclinical osteosarcoma models

Telomir Pharmaceuticals has reported early anti-cancer activity for Telomir-Zn in human and canine osteosarcoma cell models. The preclinical findings could support further research with Ohio State, including a potential study in dogs with naturally occurring osteosarcoma.

Telomir Pharmaceuticals says early laboratory work has found anti-cancer activity for Telomir-Zn in human and canine osteosarcoma models. The company is now weighing next steps with Ohio State, including a possible animal study in naturally occurring canine disease.

In research carried out with The Ohio State University College of Veterinary Medicine under Shay Bracha, Telomir-Zn was tested in three osteosarcoma cell lines: HOS, D17 and Abrams. Telomir said the compound inhibited growth in all three models at similarly low concentrations, with a dose-dependent effect. The findings, according to the company, may provide a translational route into veterinary oncology while also informing its wider oncology pipeline.

Telomir has been positioning Telomir-Zn as a candidate that targets intracellular iron and copper balance, disrupts labile iron pools and inhibits iron-dependent histone demethylases. Those claims remain preclinical, and the company acknowledged that further in vivo and clinical work will be needed to establish safety and efficacy.

The osteosarcoma data come as Telomir also advances its triple-negative breast cancer programme towards site initiation and Phase 1/2 enrolment under an active FDA-cleared investigational new drug application. For now, the Ohio State collaboration offers an early proof point rather than clinical validation.